Multivariate regression identified independent factors influencing composite endpoint events and LVEDD, including Killip classification ≥2, obesity, use of vasoactive drugs, pre-admission history of cardiomyopathy, NT-proBNP, uric acid, albumin, and the use of spironolactone, diuretics, and digoxin (All <i>P</i> values < 0.05).<h4>Conclusion</h4>LVEDD measurement within 24 hours of admission is crucial for predicting composite endpoint events in STEMI patients. The gene discussed is ALB; the disease is cardiomyopathy.